Doximity stock price target raised to $62 from $55 at Wells Fargo

Wells Fargo raised its price target on Doximity (NYSE:DOCS) to $62.00 from $55.00, citing a strong drug pipeline, AI Scribe rollout, and positive commercial pharmaceutical activity. Despite the higher target, the firm maintained an Equal Weight rating, noting that the "growth debate remains front and center" for the physician-focused digital platform. Trading near $58.18 with a 90.2% gross profit margin, DOCS has seen Wells Fargo adjust its FY26 forecast to the top end of guidance, aligning with other positive analyst reports from Leerink and Evercore ISI, yet reflecting a nuanced outlook on its future growth trajectory in a shifting digital advertising market.

Analysis

Doximity (DOCS) is receiving increased analyst attention, highlighted by Wells Fargo raising its price target to $62.00 from $55.00, citing catalysts such as the AI Scribe rollout, a robust drug pipeline, and positive pharmaceutical commercial activity. The company exhibits strong financial health, evidenced by a 90.2% gross profit margin. However, a central tension exists surrounding its growth trajectory; after posting annual growth of 22.0% in FY23 and 13.5% in FY24, the company's guidance for FY26 indicates a significant deceleration to a 10% midpoint. Despite this, Wells Fargo has adjusted its forecast to the high end of Doximity's guidance. This cautious optimism, reflected in a maintained Equal Weight rating, contrasts with more bullish outlooks from Leerink Partners and Evercore ISI, which hold Outperform ratings with price targets of $73.00 and $70.00, respectively. These firms point to conservative guidance and margin expansion potential. The backdrop includes an uncertain pharmaceutical advertising market, but Doximity is benefiting from a structural shift to digital and is reportedly seeing clients plan a 16% budget increase for calendar year 2025.

Key Decisions for Investors

• Investors should weigh the company's strong fundamentals, such as its 90.2% gross profit margin and positive product catalysts, against the significant deceleration in guided revenue growth for FY26, which remains the central debate.
• Note the divergence in analyst ratings; while Wells Fargo's Equal Weight rating suggests the current price near $58 reflects a balanced risk/reward, more bullish firms see upside potential above $70, indicating the market is still pricing in the growth uncertainty.
• Monitor upcoming Q1 FY26 earnings for any revision to the 9%-11% full-year guidance, and track commentary on the adoption of AI Scribe and pharma client budgets as key indicators for future performance.